Title / AuthorYear
Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer
K Fizazi, NP Tran, L Fein, N Matsubara, A Rodriguez-Antolin, ...
New England Journal of Medicine 377 (4), 352-360
2017
Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial
P Ost, D Reynders, K Decaestecker, V Fonteyne, N Lumen, A DeBruycker, ...
American Urological Association Education and Research, Inc.
2017
Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ...
European urology 73 (2), 178-211
2018
Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial
LMS Boevé, MCCM Hulshof, AN Vis, AH Zwinderman, JWR Twisk, ...
European urology 75 (3), 410-418
2019
Management of prostate cancer in elderly patients: recommendations of a task force of the International Society of Geriatric Oncology
JP Droz, G Albrand, S Gillessen, S Hughes, N Mottet, S Oudard, H Payne, ...
European urology 72 (4), 521-531
2017
Impact of 68Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis
S Han, S Woo, YJ Kim, CH Suh
European urology 74 (2), 179-190
2018
Third-line treatment and 177 Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
FE von Eyben, G Roviello, T Kiljunen, C Uprimny, I Virgolini, K Kairemo, ...
European journal of nuclear medicine and molecular imaging 45 (3), 496-508
2018
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
M Smith, C Parker, F Saad, K Miller, B Tombal, QS Ng, M Boegemann, ...
The Lancet Oncology 20 (3), 408-419
2019
Current status of theranostics in prostate cancer
I Virgolini, C Decristoforo, A Haug, S Fanti, C Uprimny
European journal of nuclear medicine and molecular imaging 45 (3), 471-495
2018
PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival
K Rahbar, M Boegemann, A Yordanova, M Eveslage, M Schäfers, ...
European Journal of Nuclear Medicine and Molecular Imaging 45 (1), 12-19
2018
Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study
L Triggiani, F Alongi, M Buglione, B Detti, R Santoni, A Bruni, ...
British journal of cancer 116 (12), 1520-1525
2017
68 Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review
J Corfield, M Perera, D Bolton, N Lawrentschuk
World journal of urology 36 (4), 519-527
2018
A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)
N Radwan, R Phillips, A Ross, SP Rowe, MA Gorin, ES Antonarakis, ...
BMC cancer 17 (1), 1-9
2017
Comparison of 68Ga-PSMA-11 and 18F-fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence
J Calais, WP Fendler, K Herrmann, M Eiber, F Ceci
Journal of Nuclear Medicine 59 (5), 789-794
2018
68 Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy–diagnostic performance and impact on therapeutic decision-making
B Grubmüller, P Baltzer, D D’andrea, S Korn, AR Haug, M Hacker, ...
European journal of nuclear medicine and molecular imaging 45 (2), 235-242
2018
Laparoscopic and robot‐assisted vs open radical prostatectomy for the treatment of localized prostate cancer: a Cochrane systematic review
D Ilic, SM Evans, CA Allan, JH Jung, D Murphy, M Frydenberg
BJU international 121 (6), 845-853
2018
The impact of positron emission tomography with 18F-fluciclovine on the treatment of biochemical recurrence of prostate cancer: results from the LOCATE trial
GL Andriole, L Kostakoglu, A Chau, F Duan, U Mahmood, DA Mankoff, ...
The Journal of urology 201 (2), 322-331
2019
Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group
FE Lecouvet, DE Oprea-Lager, Y Liu, P Ost, L Bidaut, L Collette, ...
The Lancet Oncology 19 (10), e534-e545
2018
TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer
B De Laere, S Oeyen, M Mayrhofer, T Whitington, PJ van Dam, ...
Clinical Cancer Research 25 (6), 1766-1773
2019
Clinical performance of 68 Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy
B Kranzbühler, H Nagel, AS Becker, J Müller, M Huellner, P Stolzmann, ...
European journal of nuclear medicine and molecular imaging 45 (1), 20-30
2018
1 - 20
Dates and citation counts are estimated and are determined automatically by a computer program.